Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vaxcyte, Inc. (US92243G1085.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
42.40-0.40 (-0.93%)
At close: 07:07PM CET
Advertisement
Full screen
Loading interactive chart...
  • Simply Wall St.

    We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Benzinga

    This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst

    Vaxcyte Inc (NASDAQ: PCVX) is Needham's top pick for 2023 and has been added to the Needham Conviction list and raised the price target to $58 from $52. The analyst writes that the positive initial VAX-24 Phase 1/2 results in October 2022 significantly de-risked the company's VAX-24 Pneumococcal Conjugate Vaccine (PCV) lead program, thus increasing conviction for a similarly optimistic outcome for the upcoming initial Phase 1/2 data readout in adults 65+ y/o in 1H23. The analyst sees an upside i

  • TipRanks

    TipRanks ‘Perfect 10’ List: These 3 Top-Rated Stocks Could Shine in 2023

    As we head into the final stretch of 2022, with less than three weeks until we turn the page to 2023, the markets and the economy are sending a series of mixed signals. Stocks have leveled out somewhat over the past month, with reduced volatility compared to the previous six months. At the same time, investors must consider the economic signals – especially persistently high inflation and uncertainty over the Federal Reserve’s interest rate decision this week. It’s a difficult environment for ma

Advertisement
Advertisement